Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by EHAB Y HANNA and YOKO TAKAHASHI.
EHAB Y HANNA
Connection Strength
3.353
YOKO TAKAHASHI
  1. Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma. Oral Oncol. 2019 10; 97:56-61.
    View in: PubMed
    Score: 0.723
  2. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head Neck. 2019 08; 41(8):2688-2695.
    View in: PubMed
    Score: 0.705
  3. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck. 2014 Aug; 36(8):1094-102.
    View in: PubMed
    Score: 0.484
  4. Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma. Clin Cancer Res. 2012 Nov 15; 18(22):6178-87.
    View in: PubMed
    Score: 0.449
  5. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. J Neurol Surg B Skull Base. 2023 Aug; 84(4):307-319.
    View in: PubMed
    Score: 0.221
  6. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622.
    View in: PubMed
    Score: 0.195
  7. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017 Jun 06; 116(12):1564-1571.
    View in: PubMed
    Score: 0.155
  8. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. 2016 04; 38 Suppl 1:E1926-34.
    View in: PubMed
    Score: 0.141
  9. Molecular profiling of sinonasal undifferentiated carcinoma. Head Neck. 2014 Jan; 36(1):15-21.
    View in: PubMed
    Score: 0.117
  10. Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach. Transl Oncol. 2024 Apr 08; 44:101943.
    View in: PubMed
    Score: 0.062
  11. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer. 2022 02; 162:221-236.
    View in: PubMed
    Score: 0.053
  12. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 2011 Apr 01; 17(7):1815-27.
    View in: PubMed
    Score: 0.025
  13. Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC. Cancer Biol Ther. 2010 Sep 15; 10(6):644-53.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.